Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).

Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M.

J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340. [Epub ahead of print]

PMID:
31609637
2.

[Correction: Systemic Therapy of Metastatic Colorectal Cancer].

Modest DP, von Bergwelt-Baildon M.

Zentralbl Chir. 2019 Jun;144(3):e1. doi: 10.1055/a-0981-6770. Epub 2019 Sep 16. German. No abstract available.

PMID:
31525781
3.

[Systemic Therapy of Metastatic Colorectal Cancer].

Modest DP, von Bergwelt-Baildon M.

Zentralbl Chir. 2019 Jun;144(3):252-258. doi: 10.1055/a-0895-6007. Epub 2019 Jun 5. German. Erratum in: Zentralbl Chir. 2019 Jun;144(3):e1.

PMID:
31167268
4.

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial.

von Einem JC, Guenther C, Volk HD, Grütz G, Hirsch D, Salat C, Stoetzer O, Nelson PJ, Michl M, Modest DP, Holch JW, Angele M, Bruns C, Niess H, Heinemann V.

Int J Cancer. 2019 Sep 15;145(6):1538-1546. doi: 10.1002/ijc.32230. Epub 2019 Mar 13.

PMID:
30801698
5.

Treatment sequencing in metastatic colorectal cancer.

Modest DP, Pant S, Sartore-Bianchi A.

Eur J Cancer. 2019 Mar;109:70-83. doi: 10.1016/j.ejca.2018.12.019. Epub 2019 Jan 25. Review.

PMID:
30690295
6.

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.

Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY.

Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24.

7.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Jelas I, Modest DP, Westphalen CB, von Einem JC, Michl M, Heinemann V.

Eur J Cancer. 2019 Jan;106:115-125. doi: 10.1016/j.ejca.2018.10.001. Epub 2018 Nov 27.

PMID:
30496943
8.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

Modest DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Stahler A, Jung A, Kirchner T, Held S, Stintzing S, Giessen-Jung C, Heinemann V; XELAVIRI/AIO KRK0110 Investigators.

J Clin Oncol. 2019 Jan 1;37(1):22-32. doi: 10.1200/JCO.18.00052. Epub 2018 Nov 2.

PMID:
30388045
9.

CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.

Froelich MF, Heinemann V, Sommer WH, Holch JW, Schoeppe F, Hesse N, Baumann AB, Kunz WG, Reiser MF, Ricke J, D'Anastasi M, Stintzing S, Modest DP, Kazmierczak PM, Hofmann FO.

Eur Radiol. 2018 Dec;28(12):5284-5292. doi: 10.1007/s00330-018-5454-7. Epub 2018 Jun 7.

PMID:
29882070
10.

Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.

Winter KS, Hofmann FO, Thierfelder KM, Holch JW, Hesse N, Baumann AB, Modest DP, Stintzing S, Heinemann V, Ricke J, Sommer WH, D'Anastasi M.

Eur Radiol. 2018 Nov;28(11):4839-4848. doi: 10.1007/s00330-018-5424-0. Epub 2018 May 7.

PMID:
29736851
11.

Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.

Hofmann FO, Holch JW, Heinemann V, Ricard I, Reiser MF, Baumann AB, Hesse N, D'Anastasi M, Modest DP, Stintzing S, Sommer WH.

Eur J Radiol. 2018 Mar;100:124-129. doi: 10.1016/j.ejrad.2018.01.006. Epub 2018 Jan 6.

PMID:
29496069
12.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V.

Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

13.

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.

Modest DP, Denecke T, Pratschke J, Ricard I, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Modest HI, Held S, Folprecht G, Heinemann V, Neumann UP.

Eur J Cancer. 2018 Jan;88:77-86. doi: 10.1016/j.ejca.2017.10.028. Epub 2017 Nov 28.

PMID:
29195117
14.

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial.

von Einem JC, Peter S, Günther C, Volk HD, Grütz G, Salat C, Stoetzer O, Nelson PJ, Michl M, Modest DP, Holch JW, Angele M, Bruns C, Niess H, Heinemann V.

Oncotarget. 2017 Sep 16;8(46):80156-80166. doi: 10.18632/oncotarget.20964. eCollection 2017 Oct 6.

15.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.

16.

Multidisciplinary treatment of colorectal liver metastases.

Schiergens TS, von Einem J, Thomas MN, Albertsmeier M, Giessen-Jung C, Dörsch M, Heiliger C, Drefs M, Andrassy J, Modest DP, Stintzing S, Guba M, Angele M, Werner J, Rentsch M.

Minerva Med. 2017 Dec;108(6):527-546. doi: 10.23736/S0026-4806.17.05371-X. Epub 2017 Sep 8. Review.

PMID:
28889727
17.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.

PMID:
28843184
18.

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.

Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S.

Oncoimmunology. 2017 Mar 31;6(5):e1310358. doi: 10.1080/2162402X.2017.1310358. eCollection 2017.

19.

Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer.

Holch JW, Demmer M, Lamersdorf C, Michl M, Schulz C, von Einem JC, Modest DP, Heinemann V.

Visc Med. 2017 Mar;33(1):70-75. doi: 10.1159/000454687. Epub 2017 Feb 7.

20.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.

Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP.

Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510.

PMID:
28582279
21.

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.

Baechmann S, Ormanns S, Haas M, Kruger S, Remold A, Modest DP, Kirchner T, Jung A, Werner J, Heinemann V, Boeck S.

BMC Cancer. 2017 May 26;17(1):374. doi: 10.1186/s12885-017-3376-4.

22.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators.

Eur J Cancer. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29.

PMID:
28463756
23.

FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?

Modest DP, Neumann UP, Pratschke J.

Eur J Cancer. 2017 Mar;73:71-73. doi: 10.1016/j.ejca.2016.12.005. Epub 2017 Jan 9. No abstract available.

PMID:
28081915
24.

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; FIRE-3 study investigators.

Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8.

25.

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V.

Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.

PMID:
27907852
26.

Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.

Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Kirchner T, Werner J, Heinemann V, Boeck S.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2585-2591. Epub 2016 Sep 14.

PMID:
27629876
27.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators.

Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. Erratum in: Lancet Oncol. 2016 Nov;17 (11):e479.

PMID:
27575024
28.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

29.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group.

Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27.

PMID:
27234640
30.

Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer.

Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Michl M, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Niyazi M, Roeder F, Kirchner T, Werner J, Heinemann V, Boeck S.

Pancreatology. 2016 Jul-Aug;16(4):593-8. doi: 10.1016/j.pan.2016.03.016. Epub 2016 Mar 30.

PMID:
27067420
31.

Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon.

Modest DP, Held S, Heinemann V.

J Clin Oncol. 2016 May 1;34(13):1565-6. doi: 10.1200/JCO.2015.66.3799. Epub 2016 Mar 7. No abstract available.

PMID:
26951313
32.

[Use of tumor markers as screening tools - sense or nonsense?].

Modest DP, Heinemann V.

Dtsch Med Wochenschr. 2015 Sep;140(19):1438-41. doi: 10.1055/s-0041-105626. Epub 2015 Sep 24. German.

PMID:
26402180
33.

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).

Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP.

Int J Cancer. 2016 Feb 1;138(3):739-46. doi: 10.1002/ijc.29807. Epub 2015 Sep 18.

34.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V.

J Clin Oncol. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10.

PMID:
26261259
35.

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).

Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR.

Eur J Cancer. 2015 Sep;51(14):1927-36. doi: 10.1016/j.ejca.2015.06.116. Epub 2015 Jul 15. Review.

PMID:
26188850
36.

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

Camaj P, Primo S, Wang Y, Heinemann V, Zhao Y, Laubender RP, Stintzing S, Giessen-Jung C, Jung A, Gamba S, Bruns CJ, Modest DP.

Future Oncol. 2015;11(13):1919-29. doi: 10.2217/fon.15.97.

PMID:
26161928
37.

Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D, Stieber P.

Tumour Biol. 2015 Sep;36(10):7897-906. doi: 10.1007/s13277-015-3522-z. Epub 2015 May 8.

PMID:
25953265
38.

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.

Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Modest DP, Stintzing S, Haas M.

Acta Oncol. 2015 Jul;54(7):993-1000. doi: 10.3109/0284186X.2015.1034877. Epub 2015 Apr 30.

PMID:
25924969
39.

NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.

Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.

40.

Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.

Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP.

Anticancer Drugs. 2015 Apr;26(4):371-8. doi: 10.1097/CAD.0000000000000196.

PMID:
25514114
41.

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C, von Einem JC, Ormanns S, Laubender RP, Holdenrieder S, Heinemann V, Boeck S.

Tumour Biol. 2015 Apr;36(4):2631-40. doi: 10.1007/s13277-014-2885-x. Epub 2014 Dec 4.

PMID:
25472579
42.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S.

Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.

PMID:
25088940
43.

Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C.

Tumour Biol. 2014 Oct;35(10):10237-48. doi: 10.1007/s13277-014-2338-6. Epub 2014 Jul 17.

PMID:
25027407
44.

Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.

Michl M, Koch J, Laubender RP, Modest DP, Giessen C, Schulz Ch, Heinemann V.

Tumour Biol. 2014 Oct;35(10):10121-7. doi: 10.1007/s13277-014-2280-7. Epub 2014 Jul 15.

PMID:
25023402
45.

Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Schulz C, Mansmann U, Heinemann V.

Acta Oncol. 2015 Feb;54(2):187-93. doi: 10.3109/0284186X.2014.938830. Epub 2014 Jul 14. Review.

PMID:
25017379
46.

Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.

Laubender RP, Lynghjem J, D'Anastasi M, Heinemann V, Modest DP, Mansmann UR, Sartorius U, Schlichting M, Graser A.

Eur Radiol. 2014 Jul;24(7):1521-8. doi: 10.1007/s00330-014-3195-9. Epub 2014 May 10.

PMID:
24816938
47.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.

von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP.

J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14. doi: 10.1007/s00432-014-1678-3. Epub 2014 May 10.

48.

[Chemotherapy of metastatic colorectal cancer].

Modest DP, Hiddemann W, Heinemann V.

Internist (Berl). 2014 Jan;55(1):37-42. doi: 10.1007/s00108-013-3314-8. German.

PMID:
24399471
49.

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).

Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V.

Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041.

PMID:
24201305
50.

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.

Ann Oncol. 2013 Dec;24(12):3051-5. doi: 10.1093/annonc/mdt402. Epub 2013 Oct 14.

PMID:
24130263

Supplemental Content

Loading ...
Support Center